Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting

Core Insights - Telo Genomics presented its innovative approach to Minimal Residual Disease (MRD) testing for Multiple Myeloma at the 67th American Society of Hematology Annual Meeting, showcasing the potential of its TeloView® 3D telomere profiling platform [1][4] Company Overview - Telo Genomics is a biotech company focused on developing diagnostic and prognostic tests for human diseases through telomere analysis, with applications in oncology and neurological diseases [9] - The company aims to provide actionable insights for medical professionals treating Multiple Myeloma, a challenging blood cancer [9] MRD Testing Insights - The new MRD evaluation method combines the enumeration of individual MM Circulating Tumor Cells (CTCs) from peripheral blood with the TeloView® platform, achieving a detection limit of 1 in 10^7 [2] - TeloView® has identified distinct 3D genome profile clusters that correlate with mutation rates, with larger studies planned to validate these MRD profiles for predicting relapse risks [3] Market Potential - The global MRD testing market is projected to reach USD 4.1 billion by 2032, driven by advancements in drug development and personalized healthcare [6] - The total addressable market for Multiple Myeloma assays is over 750,000 tests per year in the US, highlighting significant demand for MRD testing [8] Clinical Relevance - MRD is defined as the small number of cancer cells remaining post-treatment, providing critical information for clinicians regarding patient remission status [5] - The FDA's acceptance of MRD as a clinical endpoint for accelerated approval of new therapies in Multiple Myeloma indicates a shift towards more rapid drug approvals [5]